NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

Rhea-AI Summary

NeOnc Technologies (NASDAQ: NTHI), a multi-Phase 2 clinical-stage biotech company, has completed all contingencies for a $50 million strategic partnership with Quazar Investment following the incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market (ADGM).

The partnership involves Quazar Investment taking majority control of NuroMENA Holdings, which will serve as NeOnc's UAE-based subsidiary overseeing regional clinical operations in the Middle East and North Africa. The collaboration aims to accelerate the development of NeOnc's CNS therapeutic pipeline, including the NEO212 and NEO100 clinical programs for brain cancer treatment.

Quazar Investment, managing over $3.3 billion in assets, will provide strategic support to expand NeOnc's CNS platform across the MENA region, with joint governance oversight between both companies.

Positive

• Secured substantial $50 million strategic investment from Quazar Investment
• Partnership with Quazar ($3.3B AUM) provides strong financial backing and regional expertise
• Successful incorporation in ADGM enables regional expansion in MENA markets
• Strategic majority control structure established with joint governance oversight

Negative

• Dilution of control as Quazar Investment will have majority ownership of NuroMENA Holdings
• Execution risks in expanding operations to new geographic markets

News Market Reaction – NTHI

+6.68%

5 alerts

+6.68% News Effect

+4.3% Peak in 3 hr 40 min

+$6M Valuation Impact

$100.66M Market Cap

0.4x Rel. Volume

On the day this news was published, NTHI gained 6.68%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.3% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $100.66M at that time.

Data tracked by StockTitan Argus on the day of publication.

 

Quazar Chairman and Executive Team with NeOnc’s Executive’s and Directors at Quazar’s Headquarters in Dubai.

CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Aug. 11, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, announced today the official incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market (ADGM). With this regulatory milestone completed, all contingencies have now been met to finalize the previously announced $50 million cornerstone investment effort led by Quazar Investment into NuroMENA Holdings Ltd.

This strategic partnership will support the launch of NeOnc’s innovative CNS platform across the MENA region and help to accelerate development of its therapeutic pipeline, including the NEO212 and NEO100 clinical programs.

“We view this as a defining moment for NeOnc and a major validation of our global vision,” said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies. “With the finalization of NuroMENA’s incorporation and the support of Quazar Investment, we are now fully equipped ot continue our goals toward delivering life-saving therapies to a region in urgent need of innovation. This partnership not only brings capital it brings conviction, commitment, and alignment on purpose.”

Waleed K. Al Ali, Chairman and CEO of Quazar Investment, added: “We are proud to partner with NeOnc to bring cutting edge biotechnology to the UAE and beyond. With NuroMENA now officially formed under ADGM, we are positioned to assist NeOnc with efforts to transform the landscape of brain cancer and CNS treatment across the region. This is just the beginning.”

About NuroMENA Holdings Ltd.
NuroMENA is a UAE-based subsidiary of NeOnc Technologies Holdings, Inc., established as part of the UAE structure to oversee regional clinical operations, partnerships, and innovation in the Middle East and North Africa. Upon closing of the $50 million investment and execution of the change of control, NuroMENA will be majority-controlled by Quazar Investment, with joint governance oversight and strategic alignment between NeOnc and Quazar to assist accelerating breakthrough CNS therapies across the region. NuroMENA was officially incorporated under ADGM on August 6, 2025.

About NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI)
NeOnc Technologies is a multi–Phase 2 clinical-stage biotechnology company focused on novel therapies for brain cancer and other CNS disorders. With a robust IP portfolio and strong academic collaborations, NeOnc is committed to transforming outcomes in one of the hardest-to-treat areas of oncology.

About Quazar Investment
Quazar Investment is a leading strategic investment firm headquartered in Abu Dhabi, managing over $3.3 billion in assets under management (AUM). Backed by key partnerships with the UAE Government, Quazar focuses on transformative investments in biotechnology, healthcare, and next-generation infrastructure across the MENA region and globally.

“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
info@neonc.com

Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
James@haydenir.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6522c372-115c-4a62-a755-8faa7119124f

FAQ

What is the value of the strategic partnership between NeOnc Technologies (NTHI) and Quazar Investment?

The strategic partnership is valued at $50 million, with Quazar Investment leading the cornerstone investment into NuroMENA Holdings Ltd.

What is NuroMENA Holdings and how does it relate to NeOnc Technologies (NTHI)?

NuroMENA Holdings is a UAE-based subsidiary of NeOnc Technologies, incorporated under ADGM to oversee regional clinical operations and partnerships in the Middle East and North Africa region.

Who will control NuroMENA Holdings after the investment?

After the $50 million investment, Quazar Investment will have majority control of NuroMENA Holdings, with joint governance oversight shared with NeOnc Technologies.

What therapeutic programs will the NTHI-Quazar partnership accelerate?

The partnership will accelerate the development of NeOnc's CNS therapeutic pipeline, including the NEO212 and NEO100 clinical programs for brain cancer treatment.

How large is Quazar Investment as a strategic partner for NTHI?

Quazar Investment is a significant strategic partner, managing over $3.3 billion in assets and maintaining key partnerships with the UAE Government.